Dr. Zelenetz on Zanubrutinib Research in MCL

Andrew D. Zelenetz, MD, PhD
Published: Friday, Oct 18, 2019



Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses research with zanubrutinib (BGB-3111) in mantle cell lymphoma (MCL).

In August 2019, the FDA granted a priority review designation to a new drug application for zanubrutinib for the treatment of patients with MCL who received at least 1 prior therapy.

Zanubrutinib has a more restricted kinome compared with ibrutinib (Imbruvica), and in that way is similar to acalabrutinib (Calquence), explains Zelenetz. It is a highly selective BTK inhibitor that has antitumor activity in MCL as well as chronic lymphocytic leukemia.

Results from a phase I/II study (NCT02343120) demonstrated encouraging activity with zanubrutinib in patients with relapsed/refractory MCL. Accordingly, a phase II study (NCT03206970) was launched in China, which showed a high overall response rate and complete response rate. These results were higher than expected for a single-agent BTK inhibitor, says Zelenetz. However, an independent response committee confirmed these responses, Zelenetz concludes.
SELECTED
LANGUAGE


Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses research with zanubrutinib (BGB-3111) in mantle cell lymphoma (MCL).

In August 2019, the FDA granted a priority review designation to a new drug application for zanubrutinib for the treatment of patients with MCL who received at least 1 prior therapy.

Zanubrutinib has a more restricted kinome compared with ibrutinib (Imbruvica), and in that way is similar to acalabrutinib (Calquence), explains Zelenetz. It is a highly selective BTK inhibitor that has antitumor activity in MCL as well as chronic lymphocytic leukemia.

Results from a phase I/II study (NCT02343120) demonstrated encouraging activity with zanubrutinib in patients with relapsed/refractory MCL. Accordingly, a phase II study (NCT03206970) was launched in China, which showed a high overall response rate and complete response rate. These results were higher than expected for a single-agent BTK inhibitor, says Zelenetz. However, an independent response committee confirmed these responses, Zelenetz concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x